DeepMed Research

Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Clinical Trials

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Phase 3

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2003-01-27

Last Posted Date: 2010-05-27

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 80

Registration Number: NCT00002926

Locations: 🇧🇪
Hopital Universitaire Erasme, Brussels, Belgium
🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇨🇿
Institute of Hematology and Blood Transfusion, Prague, Czech Republic

and more 37 locations

Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: cytarabine
Drug: imatinib mesylate

First Posted Date: 2003-01-27

Last Posted Date: 2016-01-07

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 24

Registration Number: NCT00022490

Locations: 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma

Phase 3

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2011-01-21

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 1500

Registration Number: NCT00003728

Locations: 🇵🇹
Hospital Escolar San Joao, Porto, Portugal
🇵🇹
Instituto Portugues de Oncologia Centro do Porto, SA, Porto, Portugal
🇫🇷
CHR de Besancon - Hopital Saint-Jacques, Besancon, France

and more 20 locations

Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2021-02-21

Lead Sponsor: UNICANCER

Target Recruit Count: 179

Registration Number: NCT00003650

Locations: 🇫🇷
Centre Leon Berard, Lyon, France

Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

Phase 3

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-04

Lead Sponsor: Medical Research Council

Target Recruit Count: 1800

Registration Number: NCT00003437

Locations: 🇬🇧
Oxford Radcliffe Hospital, Oxford, England, United Kingdom

Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2014-02-20

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 276

Registration Number: NCT00005603

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 17 locations

Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia

Phase 2

Terminated

Conditions: Blastic Phase Chronic Myelogenous Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions: Biological: bevacizumab
Drug: idarubicin
Drug: cytarabine

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00023920

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Not Applicable

Completed

Conditions: T-cell Childhood Acute Lymphoblastic Leukemia
Untreated Childhood Acute Lymphoblastic Leukemia

Interventions: Drug: prednisone
Drug: vincristine sulfate
Drug: daunorubicin hydrochloride
Drug: asparaginase
Drug: methotrexate
Drug: cyclophosphamide
Drug: cytarabine
Drug: mercaptopurine
Drug: leucovorin calcium
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: thioguanine
Radiation: radiation therapy
Drug: pegaspargase
Other: pharmacological study
Drug: nelarabine
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT00016302

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Phase 3

Completed

Conditions: Childhood Acute Erythroleukemia (M6)
Childhood Acute Megakaryocytic Leukemia (M7)
Childhood Acute Monoblastic Leukemia (M5a)
Childhood Acute Monocytic Leukemia (M5b)
Childhood Acute Myeloblastic Leukemia With Maturation (M2)
Childhood Acute Myeloblastic Leukemia Without Maturation (M1)
Childhood Acute Myelomonocytic Leukemia (M4)
Childhood Myelodysplastic Syndromes
Chronic Myelomonocytic Leukemia
de Novo Myelodysplastic Syndromes

Interventions: Drug: daunorubicin hydrochloride
Drug: asparaginase
Drug: therapeutic hydrocortisone
Radiation: 3-dimensional conformal radiation therapy
Drug: fludarabine phosphate
Procedure: allogeneic bone marrow transplantation
Biological: filgrastim
Drug: cytarabine
Drug: idarubicin
Drug: dexamethasone
Biological: aldesleukin
Drug: thioguanine
Drug: etoposide
Drug: methotrexate
Drug: cyclophosphamide
Drug: busulfan

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 880

Registration Number: NCT00002798

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2022-05-31

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 885

Registration Number: NCT00006455

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇦🇹
St. Anna Children's Hospital, Vienna, Austria
🇩🇪
Kinderklinik, Giessen, Germany

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy